Table 2.
Variables | Num. | NA group, events/total | Control group, events/total | RR (95% CI) | P value | Cross-study heterogeneity | |||
---|---|---|---|---|---|---|---|---|---|
χ 2 | df | I 2 (%) | P value | ||||||
Studies with no less than 8 stars according to Newcastle-Ottawa scale | |||||||||
1-year recurrence | 3 | 75/554 | 921/4124 | 0.54 [0.32, 0.91] | 0.02 | 3.09 | 2 | 35 | 0.21 |
3-year recurrence | 3 | 181/554 | 1829/4124 | 0.63 [0.38, 1.05] | 0.08 | 7.18 | 2 | 72 | 0.03 |
1-year overall survival | 3 | 430/485 | 429/561 | 1.13 [1.07, 1.20] | <0.0001 | 1.31 | 2 | 0 | 0.52 |
3-year overall survival | 2 | 141/231 | 206/411 | 2.32 [0.39, 13.89] | 0.36 | 3.92 | 1 | 74 | 0.052 |
5-year overall survival | 3 | 181/270 | 84/159 | 2.99 [0.24, 34.42] | 0.40 | 3.72 | 1 | 73 | 0.05 |
1-year disease-free survival | 3 | 314/485 | 282/561 | 1.19 [1.09, 1.44] | 0.07 | 3.99 | 2 | 50 | 0.14 |
5-year disease-free survival | 2 | 126/270 | 57/159 | 2.96 [0.24, 36.31] | 0.40 | 3.64 | 1 | 73 | 0.06 |
Studies with RCTs excluded | |||||||||
1-year recurrence | 5 | 77/584 | 930/4167 | 0.51 [0.33, 0.80] | 0.003 | 4.99 | 4 | 20 | 0.29 |
3-year recurrence | 5 | 192/584 | 1854/4167 | 0.65 [0.44, 0.95] | 0.03 | 10.25 | 4 | 61 | 0.04 |
1-year overall survival | 7 | 553/638 | 537/718 | 1.13 [1.08, 1.19] | <0.00001 | 1.95 | 6 | 0 | 0.92 |
3-year overall survival | 6 | 264/376 | 310/584 | 1.27 [1.10, 1.47] | 0.001 | 9.25 | 5 | 46 | 0.10 |
5-year overall survival | 7 | 436/580 | 360/668 | 1.39 [1.21, 1.59] | <0.00001 | 12.19 | 6 | 51 | 0.06 |
1-year disease-free survival | 10 | 565/585 | 618/1097 | 1.14 [1.02, 1.28] | 0.02 | 15.92 | 9 | 43 | 0.07 |
3-year disease-free survival | 7 | 484/1070 | 110/347 | 1.49 [1.11, 1.99] | 0.008 | 9.20 | 6 | 35 | 0.16 |
5-year disease-free survival | 6 | 189/437 | 100/308 | 1.45 [1.02, 2.13] | 0.04 | 8.83 | 5 | 43 | 0.12 |
Num.: number; RR: risk ratio; CI: confidence interval; df: degrees of freedom.